Dietmar Reichert

Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)

Manfred P. Lutz, N. Ansorge, Gleb Barmashenko, H. Bauer et autres

BACKGROUND: Not all patients with advanced pancreatic cancer (PC) profit from 2nd-line chemotherapy. We evaluated predictive factors that are routinely collected during clinical care with the aim to support an informed and shared decision. METHODS: In a prospective study across 35 German …

de (code pays fourni par la source)

See, Do, Teach

Dietmar Reichert, Ngozi Margarete Ezinwa

This chapter explores evidence supporting primary care providers’ (PCPs) professional and personal values, serving as role models for healthy lifestyle behaviors. It discusses the potential need for PCPs to integrate the six pillars of lifestyle medicine into their personal lives. By highlighting …

Lifestyle Medicine and the Primary Care Provider

R. W. Stout, Dietmar Reichert, Rebecca Kelly

EffiXane—Non-interventional study on safety and effectiveness of nab-paclitaxel (Abraxane®) + gemcitabine as first-line treatment of metastatic PDAC in a daily routine setting

Magdalena Wojtasik, R. Kuehn, Tobias Gaska, Dietmar Reichert et autres

de, gb, es, us (code pays fourni par la source)

Comparison of TKI and CPI strategies as first-line treatment of patients with advanced renal cell carcinoma: Real-world outcome data from the German research platform CARAT.

Peter J. Goebell, Martin Boegemann, Arnd Nusch, Viktor Grünwald et autres

4528 Background: Immune checkpoint inhibitors (CPI), in combination with tyrosine kinase inhibitors (TKI) or with another CPI, expanded the therapeutic options for advanced or metastatic renal cell carcinoma (mRCC) beyond TKI-Monotherapy. However, no head-to-head clinical trials comparing 1st-line (1L) CPI+CPI vs. TKI+CPI …

de (code pays fourni par la source)

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Frank Griesinger, Wilfried Eberhardt, Wolfgang M. Brueckl, Horst-Dieter Hummel et autres

Introduction: Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNSCLC treated with pembrolizumab monotherapy in …

de, ch (code pays fourni par la source)

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial

Friederike Braulke, Florian Zettl, Marita Ziepert, Andreas Viardot et autres

The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we investigated the feasibility, toxicity, and efficacy of 8 …

de (code pays fourni par la source)

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial

Viktor Grünwald, Daniel Pink, Gerlinde Egerer, Enrico Schalk et autres

This non-interventional, prospective phase IV trial evaluated trabectedin in patients with soft tissue sarcoma (STS) in real-life clinical practice across Germany. The primary endpoints were progression-free survival (PFS) rates at 3 and 6 months, as defined by investigators. Overall, 128 patients from …

de, es (code pays fourni par la source)

Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)

Marc Thill, Pauline Wimberger, Andrea Gräfe, Peter Klare et autres

PURPOSE: NIS HELENA documented outcomes in clinical routine practice of first-line therapy with P plus T and docetaxel (D) of patients with advanced HER2-positive BC and prior (neo)adjuvant T. METHODS: Between 06/2013 through 07/2016, 126 patients (in-label use of P at study …

de (code pays fourni par la source)

1496P Trabectedin for patients with advanced soft tissue sarcoma: A non-interventional, prospective, multicenter study

Viktor Grünwald, Daniel Pink, Gerlinde Egerer, Enrico Schalk et autres

de, es (code pays fourni par la source)

Abstract P2-13-16: Dual HER2-blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T. Results from a German non-interventional study (NIS) HELENA (NCT01777958)

Marc Thill, Andrea Gräfe, Peter Klare, Kerstin Lüedtke-Heckenkamp et autres

Abstract Background: Treatment of HER2 overexpressing mBC with the HER2 directed antibody combination of P and T became standard of care since marketing authorization of P based on the results of the randomized controlled CLEOPATRA trial (NCT 00567190). NIS HELENA was designed …

de (code pays fourni par la source)

Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study

Dirk Arnold, Egbert Eggers, Jens Uhlig, Dietmar Reichert et autres

INTRODUCTION: The non-interventional study (NIS) KORALLE evaluated the effectiveness and safety of bevacizumab in patients with metastatic colorectal carcinoma (mCRC) treated with bevacizumab in combination with fluoropyrimidine-based chemotherapy in the first-line setting and beyond first progression in routine clinical practice. METHODS: This …

de, ch (code pays fourni par la source)